Encouraged by positive Phase II results in non-alcoholic steatohepatitis (NASH) patients released last year, partners Novo Nordisk A/S and Gilead Sciences, Inc. are planning a Phase IIb study to investigate the safety and efficacy of semaglutide, the Danish group’s GLP-1 receptor agonist, and a fixed-dose combination of Gilead’s investigational FXR agonist cilofexor and investigational ACC inhibitor firsocostat, alone and in combination in people with advanced compensated cirrhosis due to NASH.
Novo Nordisk And Gilead Expand NASH Alliance
Duo Exploring Combo Approaches To Treat Cirrhosis
Novo Nordisk and Gilead Sciences have expanded their clinical collaboration in non-alcoholic steatohepatitis following positive data from a proof-of-concept trial.
